Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome
Phase of Trial: Phase IV
Latest Information Update: 25 Sep 2017
At a glance
- Drugs Celiprolol (Primary)
- Indications Ehlers-Danlos syndrome
- Focus Registrational; Therapeutic Use
- 25 Sep 2017 According to an Acer Therapeutics media release, company plans to file an NDA for celiprolol (EDSIVO) for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the first half of 2018, and data from this trial, which was verified by an Acer-sponsored retrospective source will be utilised to support the application.
- 25 Sep 2017 According to an Acer Therapeutics Media Release, data were published on October 30, 2010, in The Lancet.
- 25 Sep 2017 Results presented in an Acer Therapeutics Media Release.